Acute Lung Injury and the NLRP3 Inflammasome
DOI: https://doi.org/10.2147/jir.s464838
IF: 4.5
2024-06-14
Journal of Inflammation Research
Abstract:Wanjun Gu, Qi Zeng, Xin Wang, Huthaifa Jasem, Ling Ma Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China Correspondence: Ling Ma, No. 36 Sanhao Street, Heping District, Shenyang, 110004, People's Republic of China, Tel +86-18940256927, Email Acute lung injury (ALI) manifests through harm to the capillary endothelium and alveolar epithelial cells, arising from a multitude of factors, leading to scattered interstitial alterations, pulmonary edema, and subsequent acute hypoxic respiratory insufficiency. Acute lung injury (ALI), along with its more serious counterpart, acute respiratory distress syndrome (ARDS), carry a fatality rate that hovers around 30– 40%. Its principal pathological characteristic lies in the unchecked inflammatory reaction. Currently, the main strategies for treating ALI are alleviation of inflammation and prevention of respiratory failure. Concerning the etiology of ALI, NLRP3 Inflammasome is essential to the body's innate immune response. The composition of this inflammasome complex includes NLRP3, the pyroptosis mediator ASC, and pro-caspase-1. Recent research has reported that the inflammatory response centered on NLRP3 inflammasomes plays a key part in inflammation in ALI, and may hence be a prospective candidate for therapeutic intervention. In the review, we present an overview of the ailment characteristics of acute lung injury along with the constitution and operation of the NLRP3 inflammasome within this framework. We also explore therapeutic strategies targeting the NLRP3 inflammasome to combat acute lung injury. Keywords: acute lung injury, NLRP3 inflammasome, caspase-1, IL-1β, IL-18 The pandemic-causing influenza and emerging viruses have brought about sporadic spikes in global acute lung injury (ALI). ALI manifests through injury to the cells lining the alveoli and those composing the capillary walls, which leads to interstitial and alveolar edema within the lungs, thus leading to a severe shortage of oxygen causing respiratory distress. 1,2 ALI presents with reduced pulmonary capacity, diminished elasticity within the lungs, and a profound disruption of the ventilation-perfusion balance. 3 When left untreated, acute lung injury (ALI) can develop into acute respiratory distress syndrome (ARDS). 4 Despite advancements in grasping the fundamental processes that lead to acute lung injury (ALI), an effective targeted treatment for the condition remains elusive. While ALI morbidity and mortality have declined, the death rate associated with ALI and ARDS continues to hover around a staggering 30 to 40%. It is typified by an unchecked inflammatory reaction. Currently, the main strategies for treating ALI are reduction of inflammation and prevention of respiratory failure. Consequently, gaining a deeper comprehension of the inflammatory origins of ALI and stalling its advancement is crucial. The NLRP3 inflammasome, recognized as the extensively studied NLR receptor family member, is widely present across various immune cells and holds a crucial part in the body's immune system, safeguarding the body against the infiltration of infectious agents. This intricate entity comprises a detector (NLRP3), a connector (equipped with the c-terminal cysteine protease enlistment domain, ASC), and an executor (caspase-1). It is a vital element of the innate immune system, enabling the development of active caspase-1 as well as the following development and production of inflammatory cytokines IL-1β and IL-18. 5 Important functions in the inflammatory response are played by IL-1β and IL-18. Activating the NLRP3 inflammasome is a critical stage in the development of ALI. In ALI/ARDS patients, elevated IL-1β and IL-18 levels correlate with unfavorable outcomes. One study found that levels of IL-1β were markedly increased in the BALF of mice with ALI model produced by LPS, and the expression of NLRP3 protein was noticeably higher in lung tissue. The NLRP3 inflammasome acts as an important catalyst and accelerator of ALI. By coordinating the discharge of pro-inflammatory cytokines. 6 Consequently, hindering the stimulation of the NLRP3 inflammasome has the potential to be a viable method in managing ALI. In this review, we offer a succinct overview of ALI, followed by an in-depth look at the make-up and triggering of the NLRP3 inflammasome. We investigate the link between ALI and the NLRP3 inflammasome, as well as potential therapy options for ALI. Since the initial conceptualization of acute respiratory distress syndrome (ARDS) back in 1967, there has been remarkable advancement in unraveling the mechanisms underlying its onset and progression, as well as the physiological changes associated with acute lung injury (ALI). 7 ALI presents as a grave medical emergency, carr -Abstract Truncated-
immunology